Pharmacokinetic and pharmacodynamic properties of batifiban coadministered with antithrombin agents in Chinese healthy volunteers

Abstract

The combined use of batifiban, a synthetic platelet GPII b/ IIIa receptor antagonist, and antithrombin agents is an attractive option for the treatment of patients with non-ST-segment elevation (NSTE) acute coronary syndrome (ACS) and those scheduled for percutaneous coronary intervention. To observe whether antithrombin agents affect the pharmacokinetic and pharmacodynamic properties of batifiban in combination therapy and optimize clinical administration dosage of batifiban, an open-label and parallel study was conducted. Thirty healthy subjects were randomly divided into three groups, which were sequentially treated with batifiban alone, or oral coadministration of clopidogrel, aspirin and UFH, or batifiban coadministered with these antithrombin agents. Blood samples were collected at pre-specified time points. The evaluation index included the inhibition of platelet aggregation and pharmacokinetic parameters. The pharmacokinetic parameters of batifiban and batifiban coadministered with antithrombin agents showed no significant differences. The mean inhibition rate of platelet aggregation (%) suggested that neither batifiban alone nor antithrombin agents alone could provide such potent inhibition rate (>80%) to obtain the best clinical efficacy, but they had a synergistic effect on platelet inhibition. No serious adverse effects were observed. The results in these healthy subjects suggest that batifiban coadministrated with antithrombin agents could achieve optimum clinical treatment effect for patients with NSTE ACS, and also those scheduled for percutaneous coronary intervention.

Keywords

batifiban / glycoprotein IIb/ IIIa inhibitors / antithrombin agents / pharmacokinetics / pharmacodynamics

References

[1] MadanM, BerkowitzSD, TchengJE. Glycoprotein IIb/III a integrin blockade. Circulation, 1998, 98(23): 2629-2635

[2] KongDF, CaliffRM, MillerDP, et al.. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/ IIIa integrin in ischemic heart disease. Circulation, 1998, 98(25): 2829-2835

[3] SeitzRJ, SieblerM. Platelet GP IIb/ IIIa receptor antagonists in human ischemic brain disease. Curr Vasc Pharmacol, 2008, 6(1): 29-36

[4] TricociP, NewbyLK, KandzariDE, et al.. Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. Expert Rev Cardiovasc Ther, 2007, 5(3): 401-412

[5] GuminaRJ, YangEH, SandhuGS, et al.. Survival benefit with concomitant clopidogrel and glycoprotein IIb/ IIIa inhibitor therapy at ad hoc percutaneous coronary intervention. Mayo Clin Proc, 2008, 83(9): 995-1001

[6] MandavaP, ThiagarajanP, KentTA. Glycoprotein IIb/III a antagonists in acute ischaemic stroke: current status and future directions. Drugs, 2008, 68(8): 1019-1028

[7] DecalfV, SabbahL, LafontA, et al.. Gp IIb/ IIIa receptor antagonists in acute coronary syndromes with no ST elevation. Arch Mal Coeur Vaiss, 2007, 100(12): 1006-1012

[8] MoserM, BertramU, PeterK, et al.. Abciximab, eptifibatide, and tirofiban exhibit dose dependent potencies to dissolve platelet aggregates. J Cardiovas Pharmacol, 2003, 41(4): 586-592

[9] ChenH, QiaoJ, LiQ, et al.. Safety, pharmacokinetic and pharmacodynamic study of batifiban injection following single- and multiple-dose administration to healthy chinese subjects. J Huazhong Univ Sci Technol [Medi Sci], 2009, 29(1): 12-18

[10] LefkovitsJ, PlowEF, TopolEJ. Platelet glycoprotein IIb/III a receptors in cardiovascular medicine. N Engl J Med, 1995, 332(23): 1553-1559

[11] HirshJ, AnandSS, HalperinJL, et al.. For the American Heart Association. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation, 2001, 103(24): 2994-3018

[12] GoodmanSG, FitchettD, ArmstrongPW, et al.. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation, 2003, 107(2): 238-244

[13] GretlerDD. Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. Clin Ther, 2003, 25(10): 2564-2574

[14] SkrzypekA, MatysiakJ, NiewiadomyA, et al.. Synthesis and biological evaluation of 1, 3, 4-thiadiazole analogues as novel AChE and BuChE inhibitors. Eur J Med Chem, 2013, 62: 311-319

[15] GalaupA, PaciA. Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan. Expert Opin Drug Metab Toxicol, 2013, 9(3): 333-347

[16] BornGV, CrossMJ. The aggregation of blood platelets. J Physiol, 1963, 168: 178-195

[17] HarringtonRA, KleimanNS, Kottke-MarchantK, et al.. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/ IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol, 1995, 76(17): 1222-1227

[18] KereiakesDJ, LorenzT, YoungJJ, et al.. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. J Thromb Thrombolysis, 2001, 12(2): 123-127

[19] TchengJE, TalleyJD, O’SheaJC, et al.. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol, 2001, 88(10): 1097-1102

[20] The ESPRIT Investigators.. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet, 2000, 356(9247): 2037-2044

[21] TopolEJ, MoliternoDJ, HerrmannHC, et al.. For the TARGET Investigators. Comparison of two platelet glycoprotein IIb/ IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med, 2001, 344(25): 1888-1894

[22] KabbaniSS, AggarwalA, TerrienEF, et al.. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol, 2002, 89(12): 647-650

[23] WuKK, WillersonJT. Monitoring platelet function in glycoprotein IIb/ IIIa inhibitor therapy (editorial). Circulation, 2001, 103(2): 2528-2530

[24] JenningsLK, JacoskiMV, WhiteMM. The pharmacodynamics of parenteral glycoprotein IIb/ IIIa inhibitors. J Interv Cardiol, 2002, 15(1): 45-60

[25] NurdenAT, PoujolC, Durrie-JaisC, et al.. Platelet glycoprotein IIb/ IIIa inhibitors: basic and clinical aspects. Arterioscler Thromb Vasc Biol, 1999, 19(12): 2835-2840